Barclays
PCVX icon

Barclays’s Vaxcyte PCVX Stock Holding History

Barclays’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$3.42M – 5192
2024
Q1 		$3.42M Buy
+50,000
New +$3.46M ﹤0.01% 2117

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's PCVX Position: Q1 2026 in Review

Barclays reduced its Vaxcyte (PCVX) stake by 89% in Q1 2026, selling an estimated $14.3M and leaving 31,988 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2394.

Barclays first reported a position in PCVX in Q1 2022 and has held it in 17 quarters since. The position peaked at $24M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Barclays held 31,988 shares of Vaxcyte worth $1.86M as of Q1 2026.
  • Barclays sold 264,207 Vaxcyte shares in Q1 2026, an estimated $14.3M.
  • Vaxcyte made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2394 holding.
  • Barclays first reported a position in Vaxcyte in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Vaxcyte position peaked at $24M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.